South Korea’s biosimilar drug developer Samsung Bioepis today presented the long-term safety data of Epysqli (eculizumab; ...

Learn more about the effects US pharmaceutical tariffs could have on European companies and their strategies for overcoming ...

The first trilogue negotiations between EU lawmakers over the long-awaited reform to Europe’s pharmaceutical legislation will ...

Alvotech (NASDAQ: ALVO, ALVO-SDB, the "Company"), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completio ...

In Merck’s case, worries over rising competition from so-called ‘biosimilar’ generic products, which approximate the biological chemical structure of branded medicines, is behind much of the ...

President Donald J. Trump has signaled that lowering the costs of prescription drugs will be a priority for his second term.

After digesting Cardinal Health's 2025 investor day, we inched up our 2026 revenue and EPS assumptions and lifted our stage II growth rates by 50 basis points to reflect a stronger distribution market ...

Committed to serve U.S. patients and deliver economic impact of approximately $5 billion, including creation of 300 U.S. direct high skil ...

Key complex product approval in the Affordable Medicines segment this yearCommercial launch planned for third quarter of 2025 ...

Prefilled Syringe Drug Molecule Market Prefilled Syringe Drug Market to Hit $133.24B by 2035, Growing from $74.38B in 2025 The pref ...

Ahmedabad: Zydus has announced that the company has received the Establishment Inspection Report (EIR) report from the US ...

Stallergenes Greer, a global leader in allergy therapeutics, will present insightful scientific developments at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, Glasgow ...